Balancing High Production & Quality in Biopharmaceutical Generation
In therapeutic protein production, the ability to determine the right end-point for mammalian cell culture lets researchers minimize HCP (host-cell protein) contamination.
We're Moving to
The content you are trying to access has moved to new site. Explore, discover (and in certain contries, buy) our products and services on our new website. Click to visit now or you will be automatically redirected.
to view non-migrated solutions
In therapeutic protein production, the ability to determine the right end-point for mammalian cell culture lets researchers minimize HCP (host-cell protein) contamination.
Using a state-of-the-art antibody technology platform, AIMM develops desperately needed therapeutics to improve treatment of inflammatory, autoimmune and infectious diseases.